






Heath Technology Appraisal; National Institute of Health Research. (HTA 12/140/01. £1.7M). M. J. Drake, P. Abrams, P. S. Blair, C. Chapple, C. Glazener, J. Horwood, J. A. Lane, J. McGrath, S. Noble, R. Pickard, G. Taylor

5 year extension. (NIHR128478. 2018. £240k) M. J. Drake, A. Lewis, P. Abrams, P. S. Blair, C. Chapple, J. A. Lane, S. Noble, G. Taylor











UPSTREAM

- Does urodynamics reduce surgery use in male LUTS treatment, without impairing symptom outcomes?
- What is the contribution of each component of the assessment?
- How well are the tests done?
- Can we identify men at risk of bad outcome?












| University of BRISTOL | | | arac | |
|--------------------------------------|-----|--------------------|------|-------------------|
| | | Urodynamics | | Non-urodynamics |
| | n° | Mean (SD) or n (%) | n° | Mean (SD) or n (% |
| Clinical baseline characteristics | | | | |
| Comorbidities at baseline | 420 | 281 (67%) | 383 | 260 (68%) |
| DRE findings^ | | | | |
| No abnormality | 288 | 108 (38%) | 271 | 120 (44%) |
| Benign enlargement | 352 | 312 (89%) | 327 | 287 (88%) |
| Suspected prostate cancer | 273 | 16 (6%) | 241 | 8 (3%) |
| Other | 210 | 22 (10%) | 180 | 20 (11%) |
| Uroflowmetry | | | | |
| Maximum flow rate - Qmax (ml/s) | 402 | 10.0 (7.7) | 372 | 10.9 (7.4) |
| Post void residual volume - PVR (ml) | 401 | 95.0 (136.0) | 373 | 90.0 (132.0) |
| Voided volume - Vvoid (ml) | 404 | 204.5 (175.0) | 375 | 197.0 (161.0) |
| Additional (discretionary) tests | | | | |
| PSA test | | 57 (14%) | | 57 (15%) |
| Cystoscopy | | 43 (10%) | | 24 (6%) |
| Urinalysis | | 59 (14%) | | 59 (15%) |
| Urea & Electrolytes | 413 | 14 (3%) | 383 | 11 (3%) |
| Kidney Ultrasound | | 3 (1%) | | 2 (1%) |
| Cytology | | 15 (4%) | | 7 (2%) |
| Prostate volume measurement | | 18 (4%) | | 17 (4%) |



| Table 3. Primar | At 1 Nor | 8 months I <i>inferiority</i> | in both arn PSS in both confirmed | | |
|------------------|-------------|----------------------------------|---|---|--|
| Variable | N(U:R) | Urodynamics Mean (SD) | Routine care Mean (SD) | Crude difference in means (95% C.I.) | Adj. difference i means ^a (95% C.) |
| IPSS symptom que | estionnaire | | | | |
| Total IPSS Score | 340:329 | 12.61 (7.92) | 13.11 (7.86) | -0.49 (-1.69, 0.70) | -0.33 (-1.47, 0.80 |
| QoL score | 343:332 | 2.72 (1.69) | 2.74 (1.64) | -0.02 (-0.28, 0.23) | -0.07 (-0.32, 0.18 |
| | | | | | |
| | fidence lev | el for the total IPS | SS score is <1 | for QoL score is 0.5 | |

| Surge | ry rates 38% (ry rates not re | duced by UI | òs | e) |
|---|--|------------------------------------|-------------------|----------------------|
| Variable | Urodynamics [intervention] n (%) | Routine care [control] n (%) | OR* (95% C.L) | P value ^a |
| Surgery outcome | A. 7 | | | |
| Surgery conducted | 152 (38%) | 136 (36%) | 1.06 (0.78, 1.45) | 0.694 |
| No surgery | 250 (62%) | 241 (64%) | | |
| Doctor's recommendation | | | | |
| Surgery | 196 (49%) | 180 (47%) | 1.06 (0.79, 1.43) | 0.694 |
| No surgery | 201 (51%) | 200 (53%) | | |
| | ing the Doctor's recommend | ation) ^b | | |
| | | | | |
| Surgery outcome (if matchi Surgery conducted | 142 (44%) | 129 (40%) | 1.16 (0.82, 1.62) | 0.400 |





| Secondarv | outcome: Advers | se events | |
|---------------------------------------|---|------------------------------------|--|
| ,, , | | (| 128 events, all evlewed by an ndependent clinician |
| able 5a. Adverse events - Variable | - relationship to a procedure Urodynamics [intervention] n (%) | Routine care [control] n (%) | P value ^a |
| Was the event related to trea | | II (70) | |
| Probably | 82 (35%) | 71 (37%) | |
| Possibly | 22 (9%) | 12 (6%) | 0.621 |
| Unrelated | 130 (56%) | 111 (57%) | |
| Ordinal logistic regression | | | |

| 'able 6b. Secondary Outcome: I Variable | n(U:R) | TS analysis Urodynamics [intervention] n (%)/Mean (SD) | Routine care [control] n (%)/Mean (SD) | Difference in means* (95% C.L) | P value* |
|---|--|--|--|---|-------------------------------|
| ICIQ-MLUTS scores | | | | | |
| ICSmaleVS (voiding scale) ^b | 296:278 | 6.41 (4.40) | 6.19 (4.23) | 0.09 (-0.59, 0.77) | 0.791 |
| ICSmaleIS (incontinence scale)e | 295:282 | 3.87 (3.07) | 4.04 (2.81) | -0.27 (-0.67, 0.13) | 0.191 |
| ICIQ-MLUTS bother scores | | | | | |
| Daytime frequency (>8 times) | 297:284 | 84 (28%) | 75 (26%) | 1.00 (0.65, 1.52 | 0.987 |
| | | | | | |
| Adjusted for centre and baseline scores, by | | | 189 (67%) larger scores indicating n | 0.56 (0.37, 0.87) nore severe symptoms, 'Inc | 0.010 continence |
| Adjusted for centre and baseline scores, ^b V ale, on a scale of 0-24 with larger scores i Fable 7b. Secondary Outcome: 1 Variable | oiding scale, ndicating mo | on a scale of 0-20 with re severe symptoms | | | |
| Adjusted for centre and baseline scores, ^b V ale, on a scale of 0-24 with larger scores i Table 7b. Secondary Outcome: 1 Variable <i>ICIQ-MLUTSsex</i> | ioiding scale, indicating mo ICIQ-MLU n(U:R) | on a scale of 0-20 with re severe symptoms UTSsex analysis Urodynamics [intervention] n (%) | Routine care [control] n (%) | ore severe symptoms, find OR* (95% C.L.) | P value* |
| Adjusted for centre and baseline scores, ^b V rale, on a scale of 0-24 with larger scores i l'able 7b. Secondary Outcome: 1 Variable <i>ICIQ-MLUTSsex</i> Erections (reduced or nonc) | ioiding scale, indicating mo ICIQ-MLU n(U:R) 287:270 | on a scale of 0-20 with 1 re severe symptoms UTSsex analysis Urodynamics [intervention] n (%) 206 (72%) | Routine care [control] n (%) 196 (73%) | OR* (95% C.I.) 0.81 (0.55, 1.22) | P value* |
| djusted for centre and baseline scores, ¹⁰ ale, on a scale of 0-24 with larger scores i able 7b. Secondary Outcome: I Variable <i>ICIQ-MLUTSsex</i> Ercetions (reduced or none) Ejeculation (reduced or none) | ioiding scale, indicating mo ICIQ-MLU n(U:R) 287:270 286:264 | on a scale of 0-20 with 1 re severe symptoms UTSsex analysis Urodynamics [intervention] n (%) 206 (72%) 244 (85%) | Routine care [control] n (%) 196 (73%) 219 (83%) | OR* (95% C.L) 0.81 (0.55, 1.22) 1.07 (0.65, 1.76) | P value* 0.315 0.791 |
| Adjusted for centre and baseline scores, ^b V ale, on a scale of 0-24 with larger scores i Table 7b. Secondary Outcome: 1 Variable <i>ICIQ-MLUTSsex</i> | oiding scale, indicating mo CIQ-MLU n(U:R) 287:270 286:264 255:246 | on a scale of 0-20 with 1 re severe symptoms UTSsex analysis Urodynamics [intervention] n (%) 206 (72%) | Routine care [control] n (%) 196 (73%) | OR* (95% C.I.) 0.81 (0.55, 1.22) | P value* 0.315 |

| University of BRISTOL | | | | 11 Januar |
|---------------------------------------|---------|---|----------------------------------|------------|
| | | | | |
| Subgroup anal | veis | | | |
| . . | • | | | |
| Table 8. Subgroup Analyse | | IPSS score at 18 months ^b | Interaction eff | ect |
| Variable | n(U:R)* | Subgroup specific difference in means (95% C.I) | Difference in means (95% C.I) | P value |
| Subgroup analyses | | | | |
| Age | | | | |
| ≤Median | 173:164 | -0.16 (-1.88, 1.56) | | |
| >Median | 167:165 | -0.47 (-2.00, 1.06) | +0.33 (+2.60, 1.94) | 0.773 |
| Flow rate | 1 | | | |
| ≤12ml/s | 205:194 | -0.54 (-2.06, 0.98) | - | |
| >12ml/s | 123:122 | 0.21 (-1.65, 2.08) | 0.54 (-1.84, 2.92) | 0.649 |
| Maximum voided volume | 1 | | | |
| <200ml | 144:144 | +0.61 (+2.43, 1.20) | | |
| ≥200ml | 187:177 | -0.41 (-1.97, 1.15) | 0.35 (+1.99, 2.69) | 0.763 |
| Storage dysfunction | | | | |
| No nocturia | 78:65 | -0.30 (-2.56, 1.97) | | |
| Nocturia | 245:252 | 0.49 (+1.85, 0.88) | -0.60 (-3.33, 2.14) | 0.661 |
| Severity of storage LUTS ^e | 1 | | 1 | |
| Less substantial | 191:176 | -0.14 (-1.49, 1.20) | 1 | |
| More substantial | 140:143 | -0.61 (-2.63, 1.42) | -0.70 (-2.99, 1.60) | 0.542 |
| | | the analysable sample for the IPSS scor n of items 2, 4 and 7 in the IPSS question | | sion model |
| | | | | bristol.a |


Qualitative assessment Bristol Medical School

- Most felt UD useful in decision making:
 - helped clarify what was happening to themvalidated what they/clinician had suspected
 - helped realisation that had problem that needed treatment
 - helped realisation that had problem that needed treatment
 helped understand treatment options- conservative or surgery
 - inciped understand treatment options conservative of surgery
- provided the conclusive answer that need to undergo surgerySome felt UD more helpful to clinicians than themselves
 - Not involved in decision making clinician-led
 - Already decided on TURP- clinician seeking more justification

Selman LE, et al. Neurourol Urodyn: 2018:Oct. doi: 10.1002/nau.23855 bristol.ac.uk




- What is the contribution of each component of the assessment?
- How well are the tests done?
- Can we identify the men at risk of bad outcome?




Minimum clinically important difference (MCID) based on improving IPSS-QoL score by 1


| | IPSS | ICIQ |
|----------|------------|------------|
| OVERALL | -4 | -5 |
| Mild | -3 [1-14] | -2 [1-15] |
| Moderate | -4 [15-22] | -4 [16-24] |
| Severe | -8 [23-35] | -9 [25-52] |





- What is the contribution of each component of the assessment?
- How well are the tests done?
- Can we identify the men at risk of bad outcome?












- I will take you to Manchester
- You will travel very slowly, with no explanations
- I don't know how to drive
- We don't maintain our vehicles, so the brakes might be faulty
- I will pick up some strangers, and tell you to take off your clothes for the journey





• Does urodynamics reduce surgery use in male LUTS treatment, without impairing symptom outcomes?

- What is the contribution of each component of the assessment?
- How well are the tests done?
- Can we identify the men at risk of bad outcome?



| | | Synthesis |
|------|--------------------------|---|
| | History and examinat | ion |
| • | Symptom score | ICIQ-MLUTS Individual item severity and bother Voiding/ Post voiding/ Storage |
| • | Sexual function | Sometimes profound influence |
| • | Urinalysis | Exclude bladder tumour/ UTI/ inflammation |
| • | Bladder diary | Intake, nocturia, increased daytime frequency, urgency |
| • | Free flow rate | Pattern, corrected Qmax, PVR |
| • | Use of all information | n, explanatory dialogue, joint decision making |
| • | Urodynamics | Selective use not yet defined |
| | all aspects of the p | be omitted if voiding LUTS are the dominant issue, athway have been done to a suitable standard, and titent have a clear insight into the individual case |
| 2) C | University of BRISTOL | er Yvane North Bristol MHS State Bristol Uclogical Automal Institute for Health Research |

| Conclusions |
|--|
| Including Urodynamics in male LUTS assessment achieves equivalent symptomatic outcomes following treatment (non-inferiority) Surgery rates are unchanged Urodynamics is valued by patients; better understanding of their own condition, additional information for the doctor Severity bandings and MCID of IPSS and ICIQ-MLUTS Presenting symptoms are largely based on storage LUTS, yet therapy focusses on voiding LUTS The symptoms that bother the patient are best identified by ICIQ-MLUTS, due to inclusion of UUI, PMD and individual symptom bother A substantial proportion of men experience a deterioration in symptoms Many units do not maintain equipment or know how to interpret findings |
| University of BRISTOL Retainment Youte North Bristol WHS but BRISTOL Retainment You Retainment White For Health Research |
| |

